2024
Interleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor
Brösecke F, Pfau A, Ermer T, Dein Terra Mota Ribeiro A, Rubenbauer L, Rao V, Burlein S, Genser B, Reichel M, Aronson P, Coca S, Knauf F. Interleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor. Scientific Reports 2024, 14: 11323. PMID: 38760468, PMCID: PMC11101424, DOI: 10.1038/s41598-024-61808-7.Peer-Reviewed Original ResearchConceptsIL-16 levelsIL-16Dialysis patientsCardiovascular eventsConcentrations of IL-16Kidney failureUremic toxinsCardiovascular diseaseCompared to healthy individualsPlasma oxalate concentrationActivated immune cellsAssociated with cardiovascular diseaseIL-16 concentrationCytokine IL-16Cardiovascular risk factorsNo significant associationPlasma oxalateInflammatory markersImmune cellsCytokine concentrationsInterleukin-16US patientsCohort 1Cardiovascular outcomesHealthy individuals
2022
Hemodialysis and biotransformation of erythrocyte epoxy fatty acids in peripheral tissue
Liu T, Dogan I, Rothe M, Kunz J, Knauf F, Gollasch M, Luft F, Gollasch B. Hemodialysis and biotransformation of erythrocyte epoxy fatty acids in peripheral tissue. Prostaglandins Leukotrienes And Essential Fatty Acids 2022, 181: 102453. PMID: 35633593, DOI: 10.1016/j.plefa.2022.102453.Peer-Reviewed Original ResearchConceptsRed blood cellsHD treatmentHemodialysis treatmentEnd-stage renal disease patientsHydroxyeicosatetraenoic acidHydroxyeicosapentaenoic acidSingle hemodialysis treatmentChronic kidney diseaseRenal disease patientsRenal replacement therapyFatty acid statusVenous blood samplesHydroxydocosahexaenoic acidEpoxy fatty acidsCause of mortalityLOX pathwayRenal failureFatty acidsKidney diseaseDisease patientsVenous bloodCardiovascular functionAcid statusArteriovenous differenceCardiovascular disease
2021
Determinants and Outcomes Associated With Urinary Calcium Excretion in Chronic Kidney Disease
Liu J, Tio M, Verma A, Schmidt I, Ilori T, Knauf F, Mc Causland F, Waikar S. Determinants and Outcomes Associated With Urinary Calcium Excretion in Chronic Kidney Disease. The Journal Of Clinical Endocrinology & Metabolism 2021, 107: e281-e292. PMID: 34390334, PMCID: PMC8684460, DOI: 10.1210/clinem/dgab574.Peer-Reviewed Original ResearchConceptsUrinary calcium excretionChronic kidney diseaseEnd-stage kidney diseaseCalcium excretionKidney diseaseChronic Renal Insufficiency Cohort (CRIC) StudyIncident end-stage kidney diseaseLevel of CKDSelf-identified black raceAtherosclerotic cardiovascular disease eventsSerum parathyroid hormoneCardiovascular disease eventsAdverse clinical eventsAdverse clinical outcomesStage kidney diseaseBaseline eGFRCKD progressionUrinary sodiumCause mortalityCohort studyLoop diureticsThiazide diureticsClinical outcomesParathyroid hormoneVascular calcification
2019
Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic kidney disease and non-renal inflammation
Egli-Spichtig D, Imenez Silva P, Glaudemans B, Gehring N, Bettoni C, Zhang M, Pastor-Arroyo E, Schönenberger D, Rajski M, Hoogewijs D, Knauf F, Misselwitz B, Frey-Wagner I, Rogler G, Ackermann D, Ponte B, Pruijm M, Leichtle A, Fiedler G, Bochud M, Ballotta V, Hofmann S, Perwad F, Föller M, Lang F, Wenger R, Frew I, Wagner C. Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic kidney disease and non-renal inflammation. Kidney International 2019, 96: 890-905. PMID: 31301888, DOI: 10.1016/j.kint.2019.04.009.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnimalsCell LineCohort StudiesDisease Models, AnimalFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsHumansInflammatory Bowel DiseasesInterleukin-10KidneyMaleMiceMice, TransgenicMiddle AgedNuclear Receptor Subfamily 4, Group A, Member 2Primary Cell CultureRenal Insufficiency, ChronicTumor Necrosis Factor-alphaConceptsChronic kidney diseaseTumor necrosis factorPlasma FGF23Kidney diseaseFGF23 expressionFGF23 levelsNecrosis factorGrowth factor 23 levelsFibroblast growth factor 23Inflammatory cytokines tumor necrosis factorCytokines tumor necrosis factorInflammatory bowel diseaseGrowth factor 23Normal kidney functionIL10-deficient micePopulation-based cohortAntibody-mediated neutralizationOrphan nuclear receptor Nurr1Nuclear receptor Nurr1Cause mortalityRenal inflammationTNF neutralizationBowel diseaseFactor 23Kidney functionChallenges to hypertension and diabetes management in rural Uganda: a qualitative study with patients, village health team members, and health care professionals
Chang H, Hawley NL, Kalyesubula R, Siddharthan T, Checkley W, Knauf F, Rabin TL. Challenges to hypertension and diabetes management in rural Uganda: a qualitative study with patients, village health team members, and health care professionals. International Journal For Equity In Health 2019, 18: 38. PMID: 30819193, PMCID: PMC6394065, DOI: 10.1186/s12939-019-0934-1.Peer-Reviewed Original ResearchConceptsHealth care professionalsVillage health team membersHealth team membersCare professionalsRural UgandaPrevalence of hypertensionCommunity health workersIndividual health care professionalsUgandan health care systemHealth care systemLifestyle factorsDiabetes careDM managementHealth workersHypertensionPatientsNakaseke districtHealth system reformPreventable aspectsMedication accessibilityCare systemLack of awarenessRural settingsPotential roleDiabetes